Madrigal Pharmaceuticals, Inc.
MDGL
Rangering i aksjer
#1943
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Aksjekurs
$469.52
Sist synkronisert: 2026-10-20
Markedsverdi
$10.85B
Endring (1 dag)
5.02%
Endring (1 år)
9.19%
Land
US
Handel Madrigal Pharmaceuticals, Inc. (MDGL)
Kategori
Healthcare
Inntekter for Madrigal Pharmaceuticals, Inc. (MDGL)
Inntekter i Jun 2026 TTM: $1.28B
Ifølge de nyeste økonomiske rapportene til Madrigal Pharmaceuticals, Inc. er selskapets nåværende inntekter (TTM) $1.28B. I 2023 hadde selskapet inntekter på 0.00 lik inntektene i 2022, som var 0.00. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Madrigal Pharmaceuticals, Inc. fra 2001 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $1.28B | 612.77% |
| 2024 | $180.13M | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | -100.00% |
| 2011 | $7.58M | -48.77% |
| 2010 | $14.80M | -89.74% |
| 2009 | $144.25M | 5,416.06% |
| 2008 | $2.62M | 251.95% |
| 2007 | $743.00K | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | -100.00% |
| 2004 | $173.00K | -86.73% |
| 2003 | $1.30M | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | 883.25% |
US
|
|
| $2.23B | 73.53% |
US
|
|
| $15.74B | 1,126.25% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 368.97% |
NL
|
